Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02352675 · ClinicalTrials.gov registry record
Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis
A clinical trial of Congenital Heart Disease and Rotational Thromboelastometry, sponsored by Boston Children's Hospital.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT02352675 is a study of Congenital Heart Disease and Rotational Thromboelastometry that has completed, run by Boston Children's Hospital. The registered enrollment target is 40 participants, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (92% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02352675, a study of Congenital Heart Disease and Rotational Thromboelastometry, has completed, sponsored by Boston Children's Hospital.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
Lysine analogs, like tranexamic acid (TXA) or epsilon aminocaproic acid (EACA), are antifibrinolytic agents routinely administered in children undergoing different surgeries associated with a high bleeding risk (e.g. cardiac, craniofacial, and orthopedic surgeries). Although there is a growing literature regarding the pharmacokinetic characteristics of these drugs in children, the plasmatic concentration required to completely inhibit fibrinolysis remains to be determined. In this in vitro study, the investigators will use an experimental model of fibrinolysis designed for rotational thromboelastometry (ROTEM®) to determine the minimal concentration inhibiting fibrinolysis for both TXA and EACA. In addition, this study will be used to create and validate a new experimental assay to measure fibrinolysis and the effect of antifibrinolytic agents.
Conditions Studied
Interventions
- OTHER Intraoperative Blood Sample
Study Locations (1)
Massachusetts
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-03 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02352675
The ClinicalTrials.gov registry entry for NCT02352675 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 473-participant average among 63 other Congenital Heart Disease trials with a reported enrollment target (92% lower). The listed sponsor is Boston Children's Hospital, which has 462 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Congenital Heart Disease appearing as the primary indexed condition, and to 1 intervention - of which Intraoperative Blood Sample is the first listed.
NCT02352675 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT02352675 about?
NCT02352675 is a clinical study titled "Determination of the Minimal Concentration of Antifibrinolytics Required to Inhibit t-PA-activated Fibrinolysis". Lysine analogs, like tranexamic acid (TXA) or epsilon aminocaproic acid (EACA), are antifibrinolytic agents routinely administered in children undergoing different surgeries associated with a high bleeding risk (e.g. cardiac, craniofacial, and orthopedic surgeries). Although there is a growing liter...
What is the current status of trial NCT02352675?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2015-04. Estimated completion is 2016-03.
What conditions does trial NCT02352675 study?
This clinical trial studies the following conditions: Congenital Heart Disease, Rotational Thromboelastometry, Fibrinolysis.
What interventions are being tested in trial NCT02352675?
The interventions under investigation include: Intraoperative Blood Sample (OTHER).
Who is sponsoring clinical trial NCT02352675?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02352675 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Heart Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Fontan Fitness Trial
RECRUITING · NA
-
Fontan Associated Liver Disease and the Evaluation of Biomarkers for Disease Severity Assessment
RECRUITING
-
A Study of Invasive Hemodynamic for MACHD Registry
RECRUITING
-
Remote Monitoring in Pregnant Women With Congenital Heart Disease Using Wrist Wearables
RECRUITING
-
Fetal Electrophysiologic Abnormalities in High-Risk Pregnancies Associated With Fetal Demise
RECRUITING
-
PDA for Kidneys Study
RECRUITING
Explore more on PlainTrial
Congenital Heart Disease
All registered trials for this condition
Rotational Thromboelastometry
All registered trials for this condition
Massachusetts
All trials with a study site in Massachusetts
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.